Biotie, Pfizer to end PDE10 discovery phase in June '10

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Research and Markets: The Report 'PV Innovation in North America'...
Research and Markets: Vietnam Telecommunications Services Market Report:...
Research and Markets: Indonesia Soft Drinks Review 2011: consumption,...
Northampton family thank Red Cross with generous donation to county...
Research and Markets: Malaysia Soft Drinks Review 2011: consumption,...
Simon Ward - The MPC is making another policy...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Biotie, Pfizer to end PDE10 discovery phase in June '10
9 March 2010 - Finnish drug developer Biotie Therapies Oyj (HEL: BTH1V) said today the discovery phase of its research collaboration and license agreement with US pharma giant Pfizer Inc (NYSE: PFE) regarding PDE10 inhibitors for schizophrenia will end in June 2010.
To date, the programme has...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search